Fewer patients with IBD [UC or CD] receiving 5-ASA co-treatment were anti-TNFα treatment-experienced compared with those treated without 5-ASA [39.6% vs 61.9%, respectively, at induction; 37.2% vs 66.9%, respectively, for the maintenance phase]. The gene discussed is TNF; the disease is inflammatory bowel disease.